TY - JOUR
T1 - Health Care Financing Policy for Hospitalized Nephrology Patients
AU - Munoz, Eric
AU - Barrau, Lionel
AU - Goldstein, Jonathan
AU - Benacquista, Teresa
AU - Mulloy, Katherine
AU - Wise, Leslie
PY - 1988
Y1 - 1988
N2 - The Medicare diagnosis-related group (DRG) prospective payment system is now entering its 6th year, with no reported major adverse effects on the health status of the American people. Currently 13 states are using DRG prospective “all-payer systems” for hospital reimbursement; other states may adopt DRG all payer systems. In DRG all-payer systems, Medicare, Medicaid, Blue Cross, and other commercial insurers pay by the DRG mode; New York state has been all-payer since January 1, 1988. This study simulated DRG all-payer methods on a large sample (n = 558) of adult nephrology patients for a 2-year period using both federal and New York DRG reimbursements now in effect. Both Medicare and Medicaid patients had (on average) longer hospital lengths of stay and higher total hospital costs compared with patients from Blue Cross and other commercial payers. Medicare and Medicaid patients also had greater severity of illness than patients from Blue Cross or other payers. However, all payers (le, Medicaid, Blue Cross, Medicare, and commercial insurers) generated significant financial risk under our DRG all-payer scheme. These data suggest that federal, state, and private payers may be underreimbursing for the care of hospitalized nephrology patients using the DRG prospective hospital payment scheme. As DRG payment rates are further reduced compared with the real hospital costs of treating patients, both the access to and the quality of care for many nephrology patients may be jeopardized.
AB - The Medicare diagnosis-related group (DRG) prospective payment system is now entering its 6th year, with no reported major adverse effects on the health status of the American people. Currently 13 states are using DRG prospective “all-payer systems” for hospital reimbursement; other states may adopt DRG all payer systems. In DRG all-payer systems, Medicare, Medicaid, Blue Cross, and other commercial insurers pay by the DRG mode; New York state has been all-payer since January 1, 1988. This study simulated DRG all-payer methods on a large sample (n = 558) of adult nephrology patients for a 2-year period using both federal and New York DRG reimbursements now in effect. Both Medicare and Medicaid patients had (on average) longer hospital lengths of stay and higher total hospital costs compared with patients from Blue Cross and other commercial payers. Medicare and Medicaid patients also had greater severity of illness than patients from Blue Cross or other payers. However, all payers (le, Medicaid, Blue Cross, Medicare, and commercial insurers) generated significant financial risk under our DRG all-payer scheme. These data suggest that federal, state, and private payers may be underreimbursing for the care of hospitalized nephrology patients using the DRG prospective hospital payment scheme. As DRG payment rates are further reduced compared with the real hospital costs of treating patients, both the access to and the quality of care for many nephrology patients may be jeopardized.
KW - DRGs
KW - all-payer system
KW - hospital costs
KW - nephrology patients
UR - http://www.scopus.com/inward/record.url?scp=0024239172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024239172&partnerID=8YFLogxK
U2 - 10.1016/S0272-6386(88)80102-1
DO - 10.1016/S0272-6386(88)80102-1
M3 - Article
C2 - 3143261
AN - SCOPUS:0024239172
SN - 0272-6386
VL - 12
SP - 504
EP - 509
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 6
ER -